Investment Rating - The report maintains an "Outperform" rating for China Medical System Holdings (867 HK) with a target price of HK$18.63, reflecting a potential upside from the current price of HK$12.96 [2][8]. Core Insights - The company achieved a revenue of CNY8.2 billion in FY25, representing a 10% year-on-year increase, with pharmaceutical sales revenue reaching CNY9.4 billion. The gross profit margin was 71.5%, down 1.1 percentage points year-on-year. Net profit was CNY1.4 billion, a decrease of 11% year-on-year, primarily due to one-off tax impacts [3][14]. - Exclusive and innovative products drove steady sales growth, with revenue from these products increasing by 44% year-on-year. Key products contributing to this growth include Velphoro, Metoject, Ilumya, Valtoco, and Mucopolysaccharide Polysulfate Cream [4][15]. - The approval and launch of Ruxolitinib cream for vitiligo in January 2026 is expected to generate significant sales, with management projecting revenue of at least CNY500 million in 2026 and peak sales of no less than CNY6 billion [5][16]. Financial Performance - Revenue projections for FY26 and FY27 have been revised to CNY9.6 billion and CNY11.4 billion, respectively, reflecting the expected contribution from innovative product launches. Attributable net profit forecasts for FY26 and FY27 have been adjusted to CNY1.7 billion and CNY1.9 billion, respectively, due to increased R&D spending [8][18]. - The breakdown of revenue by segment for FY25 shows: Cardiovascular and cerebrovascular segment at CNY4.2 billion (+2.3% YoY), Gastroenterology/autoimmune segment at CNY3.0 billion (+3.3% YoY), Skin health segment at CNY1.1 billion (+73.2% YoY), Ophthalmology segment at CNY0.7 billion (+12.9% YoY), and Other products at CNY0.46 billion (+10.3% YoY) [20].

香港交易及結算所有限公司、香港聯合交易所有限公司及新加坡證券交易所有限公司對 本公告的內容概不負責，對其準確性或完整性亦不發表任何聲明，並表明概不就因本公 告全部或任何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 CKD患者腎功能逐漸喪失，最終出現腎衰竭。健康的腎臟會自然分泌促紅細胞生成素 (EPO) ，這種激素可促進紅細胞生成。如果腎功能受損，腎臟生成EPO水平下降或完全 不生成EPO，從而導致貧血。HIF-PHI通過增加內源性促紅細胞生成素的生成、改善鐵的 利用率和降低鐵調素的水平來促進紅細胞生成。產品中國III期臨床試驗取得了積極結 果。主要研究終點血紅蛋白（Hb）水平（第7-9周Hb平均值相對於基線的變化）結果顯 示，試驗組優於安慰劑組。擴展期研究結果顯示，產品可使Hb水平長期維持在達標水平， 且安全性良好。此外，產品還可以顯著降低鐵調素水平，糾正鐵代謝紊亂。 據估計，中國有超過1.2億CKD患者。貧血是CKD常見併發症之一。國內一項調研顯示， CKD1～5 期患者貧血患病率依次為：22.0%、37.0%、45.4%、85.1%和98.2%。血液透析 CKD貧血患者的治療達標率（血紅蛋 ...

Investment Rating - The investment rating for the company is "Buy" [2][10] Core Insights - The company is a leading domestic specialized commercialization enterprise, and its innovative transformation has initiated a new growth cycle [5][18] - The company has excellent commercialization capabilities and a comprehensive research, production, and sales layout in the Southeast Asian market [6][20] - The company has four major business segments that are progressing in synergy, with stable contributions from cardiovascular and digestive health, and new growth momentum from skin health and ophthalmology [7][19] - The innovative pipeline is entering a harvest period, with multiple innovative products nearing commercialization [8][19] - The company has strong profitability and cash flow, providing a solid safety net for its innovative transformation and maintaining a stable high dividend policy [21] Summary by Sections 1. Company Overview - Founded in 1992, the company has evolved from a pharmaceutical agency to an innovative comprehensive pharmaceutical enterprise [22] - The company has a clear shareholding structure, with the actual controller being Mr. Lin Gang [28] - The negative impact of centralized procurement has been largely digested, with revenue and profit growth turning positive in the first half of 2025 [30] 2. Commercialization Capabilities - The company has a robust commercialization system, covering over 50,000 hospitals and 300,000 retail pharmacies, supported by a professional team of approximately 4,700 academic promoters [39] - The company has established a complete strategic layout in Southeast Asia, integrating research, registration, commercialization, and manufacturing [47] 3. Business Segments - The cardiovascular segment contributes approximately 48% of revenue, with the impact of centralized procurement clearing up and new products gaining traction [54] - The digestive and autoimmune segment accounts for about 30% of revenue, with stable growth from exclusive products and significant potential from innovative products [7] - The skin health segment, operated independently by a subsidiary, has high growth potential, with plans for a separate listing to reassess its value [7] - The ophthalmology segment contributes around 8% of revenue, with a competitive product portfolio including exclusive products and newly introduced drugs [7] 4. Innovative Pipeline - The company has nearly 40 innovative products in its pipeline, with six already commercialized and several others nearing NDA submission [8][19] - Key innovative products include Y-3 for acute ischemic stroke, Dexamethasone for chronic kidney disease, and ZUNVEYL for Alzheimer's disease, with peak sales potential exceeding 10 billion [8][19] 5. Financial Forecasts - Revenue projections for 2025-2027 are estimated at 82.16 billion, 98.59 billion, and 120.28 billion respectively, with year-on-year growth rates of 10%, 20%, and 22% [9] - Net profit forecasts for the same period are 16.15 billion, 18.50 billion, and 22.38 billion, with growth rates of 0%, 15%, and 21% [9]

Core Viewpoint - Kangzheng Pharmaceutical (00867) has received approval from the National Medical Products Administration (NMPA) for clinical trials of its innovative drug CMS-D017, which is aimed at treating complement-mediated kidney diseases [1][2]. Group 1: Drug Development - CMS-D017 is a novel selective complement factor B small molecule inhibitor that targets the complement system, a crucial part of the innate immune system [2]. - The drug aims to prevent abnormal activation of the complement pathway, thereby reducing damage to target tissues and organs associated with complement dysregulation [2]. - Clinical trials will evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of CMS-D017 in healthy participants in China [1]. Group 2: Indications and Future Development - CMS-D017 is intended for the treatment of various complement-mediated kidney diseases, including IgA nephropathy, idiopathic membranous nephropathy, lupus nephritis, and C3 glomerulopathy [2]. - The drug has previously received approval for treating paroxysmal nocturnal hemoglobinuria and is also being developed for age-related macular degeneration and myasthenia gravis [2]. Group 3: Market Position and Strategy - If approved, CMS-D017 will strengthen the company's position in the kidney disease treatment market, complementing its other innovative drugs, such as Vifor (sucroferric oxyhydroxide chewable tablets for CKD hyperphosphatemia) and Daprodustat (for renal anemia) [3]. - The company is actively preparing to initiate clinical trials for CMS-D017, aiming for a swift market launch [4].

Core Viewpoint - Kangzheng Pharmaceutical has received approval from the National Medical Products Administration (NMPA) for clinical trials of its innovative drug CMS-D017, which is a selective complement factor B small molecule inhibitor aimed at treating complement-mediated kidney diseases [1][2]. Group 1: Drug Development - CMS-D017 is designed to inhibit complement factor B, a key component in the complement system that can lead to tissue damage when abnormally activated [2]. - The drug has shown excellent efficacy and safety in preclinical studies and is intended for conditions such as IgA nephropathy, idiopathic membranous nephropathy, lupus nephritis, and C3 glomerulopathy [2]. - CMS-D017 previously received clinical trial approval for treating paroxysmal nocturnal hemoglobinuria on January 30, 2026, indicating its potential for multiple therapeutic applications [2]. Group 2: Market Position and Strategy - If approved for market launch, CMS-D017 will strengthen the company's position in the kidney disease treatment sector, complementing its other innovative drugs, such as Vifor (for CKD hyperphosphatemia) and Dexamethasone (for renal anemia) [3]. - The company is actively preparing to initiate clinical trials for CMS-D017, aiming for a swift market introduction [4].

Investment Rating - The report gives an initial investment rating of "Buy" for the company 康哲药业 (00867.HK) [4][8]. Core Views - The company is positioned as a leading innovative platform in the pharmaceutical industry, with a focus on commercializing its innovative pipeline and expanding its market presence [4][7]. - The planned spin-off of 德镁医药 is expected to unlock additional value in the skin health segment, which has a comprehensive pipeline covering all indications in this area [7][8]. - The company has shown signs of a performance turnaround, with a 10.83% year-on-year increase in revenue for the first half of 2025, indicating a potential inflection point in its financial performance [7][17]. Summary by Sections Financial Performance - The company reported a total revenue of 8,013 million RMB in 2023, with a projected revenue of 8,166 million RMB in 2025, reflecting a growth rate of 9.3% [6][8]. - The net profit attributable to shareholders is expected to increase from 1,620 million RMB in 2024 to 1,681 million RMB in 2025, with a growth rate of 3.8% [6][8]. - The company’s earnings per share (EPS) is projected to be 0.69 RMB in 2025, with a return on equity (ROE) of 9.3% [6][8]. Business Strategy - 康哲药业 has undergone multiple transformations over its 30-year history, evolving from a sales agent to a company that controls product rights and now focuses on innovative product development [13][14]. - The company has diversified its business into three main segments: cardiovascular/digestive, skin health, and ophthalmology, aiming to create specialized teams for each area [21][24]. - The internationalization strategy has been accelerated with the recent listing on the Singapore Exchange, marking a significant milestone in its global expansion efforts [24][25]. Innovation and Pipeline - The company has five innovative drugs that have been commercialized in China, with several others in the NDA stage, indicating a robust pipeline for future growth [7][8]. - Key innovative products include 德昔度司他片 for chronic kidney disease anemia and ABP-671 for gout, both of which are expected to contribute significantly to future revenues [43][45]. - The company is leveraging a dual approach of collaboration and self-research to drive innovation, aiming to meet unmet clinical needs and enhance its product offerings [40][41].